Method of preparing benzimidazole derivatives or their salts

专利摘要:
The present invention relates to novel compounds of the formula wherein R' and R2 are same or different and are each hydrogen, alkyl, halogen, carbomethoxy, carbethoxy, alkoxy, or alkanoyl, R6 is hydrogen, methyl or ethyl, R3, R4 and R5 are same or different and are each hydrogen, methyl, methoxy, ethoxy, methoxyethoxy or ethoxyethoxy whereby R3, R4 and R5 are not all hydrogen, and whereby when two of R3, R4 and R5 are hydrogen the third of R3, R4 and R5 is not methyl. The compounds are potent gastric acid secretion inhibitors.
公开号:SU873880A3
申请号:SU802870599
申请日:1980-01-18
公开日:1981-10-15
发明作者:Кристер Юнггрен Ульф；Эрик Сестранд Свен
申请人:А.Б.Хессле(Фирма)；
IPC主号:

专利说明:

Continuation of table
Continuation of table 2

权利要求:
Claims (1)
[1]
Claim
A method of obtaining benzimidazole derivatives of the general formula for their salts, about l and h.
5CH1L h
„Or from the mule • where Rj, have the indicated indications, are subjected to interaction by the unity of the general formula III.
u and Forznachas СО · where 1 4- at position 4 means hydrogen or methyl, at position 5 - hydrogen, methyl, methoxy, acetyl, carbomethoxy, carboethoxy or chlorine;
R ^, Rj, RpR ^ - hydrogen or methyl;
R ^ is hydrogen, methyl, methoxy, ethoxy, or 2methoxyethoxy, take RjpR ^, Ry can be the same or different — 45 different, at the same time do not mean hydrogen, and if two of the radicals Ry mean hydrogen, then the third means methyl,
Of the values of N, where R, R and R have the indicated _ 3 4 5 ny, followed by the inclusion of the target product in free form or in the form. salt.

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU873880A3|1981-10-15|Method of preparing benzimidazole derivatives or their salts

---

KR880013888A|1988-12-22|Novel dithioacetal compound, preparation method thereof and pharmaceutical composition comprising the compound

---

JPS55136266A|1980-10-23|Derivatives of 2-imidazoline

---

PT65019B|1977-09-09|PHENYLALKANCARBONE SOWING DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF

---

IE842930L|1985-05-16|Furopyridines

---

FR2364896A1|1978-04-14|NEW ANILINE DERIVATIVES USEFUL AS AGENTS IN THE CONTROL OF PARASITES

---

JPS63135381A|1988-06-07|Sensitivity enhancer for multidrug-resistant cancerous cell and production thereof

---

JPS5618983A|1981-02-23|Theophylline derivative and its preapration

---

KR880011122A|1988-10-26|4-thioquinazolin derivatives, preparation method thereof and pharmaceutical composition

---

KR850000415A|1985-02-27|Method for preparing quinazolinone derivatives

---

JPS63301873A|1988-12-08|2-alkylsulfinyl-4-|-quinazolinone derivative, production thereof and antitumor agent containing said derivative as active ingredient

---

JPS5576872A|1980-06-10|Imidazolidinone derivative

---

JPS51133243A|1976-11-18|Process for preparing phthalamic acid ester derivatives

---

JPS5225765A|1977-02-25|Preparation of novel isoindoline derivatives

---

KR860008171A|1986-11-12|Method for preparing 4-aminoalkylidene-substituted 3-alkyl-5 | isoxazolone

---

JPS51136698A|1976-11-26|Process for preparing new pyridone carboxylic acid derivatives

---

JPS54109969A|1979-08-29|Novel method of preparing thiazole derivative

---

JPS5227757A|1977-03-02|Preparation of 6-aminomethylnaphthalene derivatives

---

JPS51136683A|1976-11-26|Process for preparing 5-| alkyl carbostyril deri vatives

---

JPS61200966A|1986-09-05|Bis|, production thereof and selective electrode using same

---

JPS5473797A|1979-06-13|Pyride 3.2.1-jk carbazole derivative

---

KR870008871A|1987-10-21|Method for preparing pyridine derivative

---

JPS5262280A|1977-05-23|Preparation of novel butyrophenone derivatives

---

KR830006204A|1983-09-20|Method for preparing naphthymidazole and naphthoxazole derivatives

---

JPS51149283A|1976-12-22|Process for preparing 5-| carbosty ril deri vatives

同族专利:

---

公开号 | 公开日

---

CS261851B2|1989-02-10|

---

DE2960293D1|1981-08-06|

---

DK151179A|1979-10-15|

---

NZ190203A|1984-03-16|

---

SU895292A3|1981-12-30|

---

JPS58192880A|1983-11-10|

---

SU873879A3|1981-10-15|

---

ATA290483A|1989-08-15|

---

FI65067C|1984-03-12|

---

BG61492B2|1997-09-30|

---

US4255431A|1981-03-10|

---

ATA273279A|1983-09-15|

---

NO791227L|1979-10-16|

---

DK150510C|1987-12-07|

---

NO152216B|1985-05-13|

---

NO152785C|1985-11-20|

---

AT374471B|1984-04-25|

---

FI65067B|1983-11-30|

---

LT2274B|1993-12-15|

---

NL930074I2|1994-02-16|

---

DK150510B|1987-03-16|

---

LU88307I2|1994-05-04|

---

NO1995006I1|1995-06-14|

---

SG63383G|1984-07-27|

---

IE790785L|1979-10-14|

---

NL930075I2|1994-02-16|

---

CA1127158A|1982-07-06|

---

SE7804231L|1979-10-15|

---

DD142882A5|1980-07-16|

---

MY8500074A|1985-12-31|

---

NO152216C|1985-08-21|

---

NO1994027I1|1994-12-21|

---

AT389995B|1990-02-26|

---

AU4602779A|1979-10-18|

---

EP0005129A1|1979-10-31|

---

CS254979A2|1988-07-15|

---

FI791219A|1979-10-15|

---

JPS54141783A|1979-11-05|

---

NO152785B|1985-08-12|

---

SU878196A3|1981-10-30|

---

JPS6353191B2|1988-10-21|

---

NL930074I1|1993-09-16|

---

US4508905A|1985-04-02|

---

EP0005129B1|1981-04-29|

---

IE48370B1|1984-12-26|

---

AU529654B2|1983-06-16|

---

JPS6034956B2|1985-08-12|

---

US4337257A|1982-06-29|

---

NO1995005I1|1995-06-14|

---

LU88305I2|1994-05-04|

---

NL930075I1|1993-09-16|

---

NO840112L|1979-10-16|

---

HU179022B|1982-08-28|

---

ZA791586B|1980-04-30|

---

HK15284A|1984-03-02|

---

CY1232A|1984-06-29|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB1234058A|1968-10-21|1971-06-03|

---

SE418966B|1974-02-18|1981-07-06|Haessle Ab|ANALOGY PROCEDURE FOR THE PREPARATION OF COMPOUNDS WITH Gastric Acid Secretion Inhibitory Effects|

---

US4045564A|1974-02-18|1977-08-30|Ab Hassle|Benzimidazole derivatives useful as gastric acid secretion inhibitors|

---

SE416649B|1974-05-16|1981-01-26|Haessle Ab|PROCEDURE FOR THE PREPARATION OF SUBSTANCES WHICH PREVENT Gastric acid secretion|

---

IN148930B|1977-09-19|1981-07-25|Hoffmann La Roche|US4359465A|1980-07-28|1982-11-16|The Upjohn Company|Methods for treating gastrointestinal inflammation|

---

CH644116A5|1980-08-21|1984-07-13|Hoffmann La Roche|IMIDAZOLE DERIVATIVES.|

---

IL66340A|1981-08-13|1986-08-31|Haessle Ab|Pharmaceutical compositions comprising pyridylmethyl-thiobenzimidazole derivatives,certain such novel derivatives and their preparation|

---

US4472409A|1981-11-05|1984-09-18|Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung|2-Pyridylmethyl thiobenzimidazoles with gastric acid secretion inhibiting effects|

---

JPS58135881A|1981-11-05|1983-08-12|Biiku Guruden Ronberugu Chem F|Substituted benzimidazoles, manufacture and use and medicine|

---

DE3216843C2|1982-05-05|1986-10-23|Ludwig Heumann & Co GmbH, 8500 Nürnberg|3-Thiomethyl-pyridine derivatives, processes for their preparation and pharmaceuticals containing these compounds|

---

SE8204879D0|1982-08-26|1982-08-26|Haessle Ab|NOVEL CHEMICAL INTERMEDIATES|

---

SE8300736D0|1983-02-11|1983-02-11|Haessle Ab|NOVEL PHARMACOLOGICALLY ACTIVE COMPOUNDS|

---

SE8301182D0|1983-03-04|1983-03-04|Haessle Ab|NOVEL COMPOUNDS|

---

IL71664A|1983-05-03|1987-11-30|Byk Gulden Lomberg Chem Fab|Fluoroalkoxy compounds,process for their preparation and pharmaceutical compositions containing the same|

---

HU191757B|1983-05-03|1987-04-28|Byk Gulden Lomberg Chem Fab|Process for producing new tricyclic ethers|

---

US5077407A|1983-07-01|1991-12-31|The Upjohn Company|Substituted 2-[monoannelatedpyridylalkylenesulfinyl]benzimidazoles|

---

CA1259070A|1983-07-01|1989-09-05|Upjohn Company |Substituted 2-¬monoannelated-pyridylalkylenesulfinyl|-benzimidazoles|

---

DE3333314A1|1983-09-15|1985-03-28|Hoechst Ag, 6230 Frankfurt|SUBSTITUTED PYRIDOIMIDAZOBENZIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS|

---

US4663347A|1983-10-31|1987-05-05|Merck Frosst Canada, Inc.|Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis|

---

US4619997A|1984-09-06|1986-10-28|The Upjohn Company|Substituted 2-pyridylmethylthio and sulfinyl-benzimidazoles as gastric antisecretory agents|

---

US4575554A|1983-12-05|1986-03-11|The Upjohn Company|Substituted 2-pyridylmethylthio- and sulfinyl-benzimidazoles as gastric antisecretory agents|

---

ZW4585A1|1984-04-19|1985-11-20|Hoffmann La Roche|Imidazole derivatives|

---

SE8403179D0|1984-06-13|1984-06-13|Haessle Ab|NEW COMPOUNDS|

---

IL75400A|1984-06-16|1988-10-31|Byk Gulden Lomberg Chem Fab|Dialkoxypyridine methylbenzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same|

---

EP0174717B1|1984-07-06|1992-01-22|FISONS plc|Benzimidazoles, and their production formulation and use as gastric acid secretion inhibitors|

---

SE8404065D0|1984-08-10|1984-08-10|Haessle Ab|NOVEL BIOLOGICALLY ACTIVE COMPOUNDS|

---

JPH0244473B2|1984-08-16|1990-10-04|Takeda Chemical Industries Ltd|

---

JPH0475914B2|1984-08-16|1992-12-02|Takeda Chemical Industries Ltd|

---

KR890000387B1|1984-09-24|1989-03-16|디 엎존 캄파니|N-substituted derivatives of 2-benzimidazoles and process for the preparation thereof|

---

SE8405588D0|1984-11-08|1984-11-08|Haessle Ab|NEW COMPOUNDS|

---

DE3579436D1|1984-12-18|1990-10-04|Otsuka Pharma Co Ltd|TETRAHYDROQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THE ANTIMAGE POTUS COMPOSITIONS CONTAINING THEM.|

---

FI861772A|1985-05-07|1986-11-08|Chemie Linz Ag|THEN THENIMIDED INSULATED FOR THE FRAME FRAMEWORK.|

---

US5869513A|1985-05-24|1999-02-09|G. D. Searle & Co.|2- methyl!benzenamines|

---

AU5768886A|1985-05-24|1986-11-27|G.D. Searle & Co.|2-methyl)benzenamines|

---

CA1309557C|1985-06-18|1992-10-27|Robert N. Young|Leukotriene antagonists|

---

US4738975A|1985-07-02|1988-04-19|Takeda Chemical Industries, Ltd.|Pyridine derivatives, and use as anti-ulcer agents|

---

AR243167A1|1985-08-24|1993-07-30|Hoechst Ag|Substituted toluidines, process for their preparation, pharmaceutical compositions containing them and their use as gastric secretion inhibitors|

---

JPS6261978A|1985-09-12|1987-03-18|Otsuka Pharmaceut Co Ltd|5-fluoro-1h-benzimidazole derivative|

---

SE8505112D0|1985-10-29|1985-10-29|Haessle Ab|NOVEL PHARMACOLOGICAL COMPOUNDS|

---

US5433959A|1986-02-13|1995-07-18|Takeda Chemical Industries, Ltd.|Stabilized pharmaceutical composition|

---

CA1327010C|1986-02-13|1994-02-15|Tadashi Makino|Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production|

---

US6749864B2|1986-02-13|2004-06-15|Takeda Chemical Industries, Ltd.|Stabilized pharmaceutical composition|

---

ES2032394T3|1986-02-20|1993-02-16|Hoechst Aktiengesellschaft|PROCEDURE FOR PREPARING SUBSTITUTED TENOIMIDAZOLE DERIVATIVES.|

---

WO1987005296A1|1986-03-07|1987-09-11|Pfizer Inc.|2-[methylsulfinyl]thienoimidazoles and related compounds as antiulcer agents|

---

EP0239306B1|1986-03-27|1993-06-02|Merck Frosst Canada Inc.|Tetrahydrocarbazole esters|

---

GB2189699A|1986-04-30|1987-11-04|Haessle Ab|Coated acid-labile medicaments|

---

GB2189698A|1986-04-30|1987-11-04|Haessle Ab|Coated omeprazole tablets|

---

US4772619A|1986-07-17|1988-09-20|G. D. Searle & Co.|[methyl]-2-pyridinamines|

---

US4687775A|1986-07-17|1987-08-18|G. D. Searle & Co.|2-[sulfinyl]-1H-benzimidazoles|

---

US4721718A|1986-08-18|1988-01-26|G. D. Searle & Co.|2-[sulfinyl]-1H-benzimidazoles useful in the treatment and prevention of ulcers|

---

CA1256109A|1986-09-10|1989-06-20|Franz Rovenszky|Process for the preparation of derivatives of 4,5-dihydrooxazoles|

---

SE8604566D0|1986-10-27|1986-10-27|Haessle Ab|NOVEL COMPUNDS|

---

FI90544C|1986-11-13|1994-02-25|Eisai Co Ltd|Process for the preparation of 2-pyridin-2-ylmethylthio and sulfinyl-1H-benzimidazole derivatives useful as medicaments|

---

AT103912T|1986-11-13|1994-04-15|Eisai Co Ltd|PYRIDINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR APPLICATION FOR THE PRODUCTION OF MEDICINAL PRODUCTS OF THERAPEUTIC OR PREVENTIVE VALUE AND METHOD FOR THE PRODUCTION THEREOF.|

---

NZ222495A|1986-11-21|1991-04-26|Haessle Ab|Benzimidazole derivatives and pharmaceutical compositions|

---

SE8604998D0|1986-11-21|1986-11-21|Haessle Ab|NOVEL PHARMACOLOGICAL COMPOUNDS|

---

DE3639926A1|1986-11-22|1988-06-01|Hoechst Ag|SUBSTITUTED THIENOIMIDAZOLTOLUIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING IT AND THEIR USE AS AN INGESTIC ACID INHIBITOR|

---

FI91754C|1986-12-02|1994-08-10|Tanabe Seiyaku Co|An analogous method for preparing an imidazole derivative useful as a medicament|

---

JPS63230633A|1987-03-19|1988-09-27|Nippon Chemiphar Co Ltd|Protecting agent for gastroenteric cell|

---

DE3719783A1|1987-06-13|1988-12-22|Hoechst Ag|METHOD FOR PRODUCING 5-PHENYLSULFINYL-1H-2-- BENZIMIDAZOLE|

---

FI96860C|1987-06-17|1996-09-10|Eisai Co Ltd|An analogous method for preparing a pyridine derivative for use as a medicament|

---

JP2718945B2|1987-06-17|1998-02-25|エーザイ株式会社|Pyridine derivative and therapeutic agent for ulcer containing the same|

---

DE3723327A1|1987-07-15|1989-02-02|Hoechst Ag|SUBSTITUTED THIENOIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE AS ANTI-ACIDIC SECRETION AGENT, ANTI-STAGE AGENT AND AS A MEDICINE AGAINST INTESTINALS|

---

DK171989B1|1987-08-04|1997-09-08|Takeda Chemical Industries Ltd|Process for the preparation of 2-benzimidazoles|

---

US5124158A|1988-06-30|1992-06-23|The Upjohn Company|Transdermal antisecretory agents for gastrointestinal disease|

---

US5223515A|1988-08-18|1993-06-29|Takeda Chemical Industries, Ltd.|Injectable solution containing a pyridyl methylsulfinylbenzimidazole|

---

KR900701270A|1988-08-23|1990-12-01|안데르스 베딘|Treatment of glaucoma and related disorders in human eyes with pyridinylmethylbenzimidazole|

---

US5075323A|1988-08-24|1991-12-24|Aktiebolaget Hassle|Compounds including omeprazole in the treatment of glaucoma|

---

US5175286A|1988-09-20|1992-12-29|Hisamitsu Pharmaceutical Co., Inc.|Dibenz[b,e]oxepin derivatives|

---

AT391693B|1988-11-15|1990-11-12|Cl Pharma|METHOD FOR PRODUCING 3-5-DIMETHYL-4METHOXYPYRIDINE DERIVATIVES AND NEW INTERMEDIATE PRODUCT THEREFOR|

---

SE8804628A|1988-12-22|1988-12-22|

---

IE64199B1|1988-12-22|1995-07-12|Haessle Ab|Compound with gastric acid inhibitory effect and process for its preparation|

---

SE8804629D0|1988-12-22|1988-12-22|Ab Haessle|NEW THERAPEUTICALLY ACTIVE COMPOUNDS|

---

JP2694361B2|1989-02-09|1997-12-24|アストラアクチエボラグ|Antibacterial agent|

---

GB2239453A|1989-11-27|1991-07-03|Haessle Ab|Omeprazole|

---

US5049674A|1989-12-20|1991-09-17|Aktiebolaget Hassle|Therapeutically active fluoro substituted benzimidazoles|

---

US5274099A|1989-12-20|1993-12-28|Aktiebolaget Hassle|Therapeutically active fluoro substituted benzimidazoles|

---

US4965269A|1989-12-20|1990-10-23|Ab Hassle|Therapeutically active chloro substituted benzimidazoles|

---

KR930000861B1|1990-02-27|1993-02-08|한미약품공업 주식회사|Omeprazole rectal composition|

---

PL172133B1|1990-04-04|1997-08-29|Chiron Corp|Method of creating a combination of antigenes of viral hematitis cand method of detecting antibodies against c |

---

SE9002043D0|1990-06-07|1990-06-07|Astra Ab|IMPROVED METHOD FOR SYNTHESIS|

---

SE9002206D0|1990-06-20|1990-06-20|Haessle Ab|NEW COMPOUNDS|

---

DE69131627T2|1990-06-20|2000-04-27|Astra Ab Soedertaelje|DIALKOXYPYRIDINYLBENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION AND THEIR PHARMACEUTICAL USE|

---

US5061805A|1990-08-10|1991-10-29|Reilly Industries, Inc.|Process for preparing 2-methyl-3,5-dialkylpyridines by dealkylation with sulfur|

---

CA2052698A1|1990-10-11|1992-04-12|Roger G. Berlin|Treatment of peptic ulcer|

---

US5428033A|1990-10-12|1995-06-27|Merck Frosst Canada, Inc.|Saturated hydroxyalkylquinoline acids as leukotriene antagonists|

---

US5312824A|1990-10-17|1994-05-17|Takeda Chemical Industries, Ltd.|Certain 2-[-methylthio or methylsulfinyl-5-benzimidazoles useful for treating peptic ulcers|

---

ES2026761A6|1990-10-31|1992-05-01|Genesis Para La Investigacion|A process for the preparation of omeprazol.|

---

WO1993006097A1|1991-09-20|1993-04-01|Merck & Co., Inc.|Novel process for the preparation of anti-ulcer agents|

---

FR2692146B1|1992-06-16|1995-06-02|Ethypharm Sa|Stable compositions of gastro-protected omeprazole microgranules and process for obtaining them.|

---

EP0649305A1|1992-07-08|1995-04-26|Monsanto Company|Benzimidazoles for alleviating stomach ulcers in swine|

---

KR100258423B1|1992-07-28|2000-07-01|클래스 빌헬름슨|Injection and injection kit containing omeprazole and its analogs|

---

SE9301830D0|1993-05-28|1993-05-28|Ab Astra|NEW COMPOUNDS|

---

US6875872B1|1993-05-28|2005-04-05|Astrazeneca|Compounds|

---

SE9302396D0|1993-07-09|1993-07-09|Ab Astra|A NOVEL COMPOUND FORM|

---

SE9302395D0|1993-07-09|1993-07-09|Ab Astra|NEW PHARMACEUTICAL FORMULATION|

---

US5410054A|1993-07-20|1995-04-25|Merck Frosst Canada, Inc.|Heteroaryl quinolines as inhibitors of leukotriene biosynthesis|

---

TW280770B|1993-10-15|1996-07-11|Takeda Pharm Industry Co Ltd|

---

WO1995011897A1|1993-10-29|1995-05-04|Yoshitomi Pharmaceutical Industries, Ltd.|Pyridine compound and medicinal use thereof|

---

US5502195A|1993-11-04|1996-03-26|Slemon; Clarke|Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole|

---

US5374730A|1993-11-04|1994-12-20|Torcan Chemical Ltd.|Preparation of omeprazole and lansoprazole|

---

KR0179401B1|1994-02-28|1999-03-20|송택선|Novel 5-pyrrolyl-2-pyridylmethylsulfanilbenzimidazole derivatives|

---

AU2395095A|1994-04-29|1995-11-29|G.D. Searle & Co.|Method of usingatpase inhibitors as antiviral agents|

---

CN1138534C|1994-07-08|2004-02-18|阿斯特拉曾尼卡有限公司|Multiple unit tableted dosage form I|

---

SE9402431D0|1994-07-08|1994-07-08|Astra Ab|New tablet formulation|

---

SE504459C2|1994-07-15|1997-02-17|Astra Ab|Process for the preparation of substituted sulfoxides|

---

GB9423970D0|1994-11-28|1995-01-11|Astra Ab|Oxidation|

---

GB9423968D0|1994-11-28|1995-01-11|Astra Ab|Resolution|

---

KR0142815B1|1994-12-02|1998-07-15|정도언|Novel 5-pyrrolyl-o-halogeno-2-pyridyl methylsulfinylbenzimidazole derivatlves|

---

SE9500422D0|1995-02-06|1995-02-06|Astra Ab|New oral pharmaceutical dosage forms|

---

SE9500478D0|1995-02-09|1995-02-09|Astra Ab|New pharmaceutical formulation and process|

---

JP3015702B2|1995-02-21|2000-03-06|株式会社アラクス|Imidazole derivatives, their pharmaceutically acceptable acid addition salts, their production, and antiulcer agents containing them as active ingredients|

---

JP3046924B2|1995-03-27|2000-05-29|株式会社アラクス|Imidazoline derivatives or their possible tautomers, methods for their preparation and wound treatments containing them as active ingredients|

---

US5708017A|1995-04-04|1998-01-13|Merck & Co., Inc.|Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors|

---

HRP960232A2|1995-07-03|1998-02-28|Astra Ab|A process for the optical purification of compounds|

---

US5686588A|1995-08-16|1997-11-11|Yoo; Seo Hong|Amine acid salt compounds and process for the production thereof|

---

US5824339A|1995-09-08|1998-10-20|Takeda Chemical Industries, Ltd|Effervescent composition and its production|

---

DE69634160T2|1995-09-21|2005-12-22|Pharma Pass Ii Llc, Irvine|An acid-labile omeprazole-containing drug composition and process for its preparation|

---

SE521100C2|1995-12-15|2003-09-30|Astra Ab|Process for the preparation of a benzimidazole compound|

---

KR970032861A|1995-12-29|1997-07-22|김준웅|Helicobacter pylori removal drug administration method|

---

US20050054682A1|1996-01-04|2005-03-10|Phillips Jeffrey O.|Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same|

---

US6489346B1|1996-01-04|2002-12-03|The Curators Of The University Of Missouri|Substituted benzimidazole dosage forms and method of using same|

---

US6699885B2|1996-01-04|2004-03-02|The Curators Of The University Of Missouri|Substituted benzimidazole dosage forms and methods of using same|

---

US6645988B2|1996-01-04|2003-11-11|Curators Of The University Of Missouri|Substituted benzimidazole dosage forms and method of using same|

---

US5840737A|1996-01-04|1998-11-24|The Curators Of The University Of Missouri|Omeprazole solution and method for using same|

---

SE9600070D0|1996-01-08|1996-01-08|Astra Ab|New oral pharmaceutical dosage forms|

---

AU1538397A|1996-02-06|1997-08-28|Pdi-Research Laboratories, Inc.|Synthesis of omeprazole-type pyridine derivatives and intermediates thereof|

---

US6623759B2|1996-06-28|2003-09-23|Astrazeneca Ab|Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof|

---

US5625069A|1996-07-22|1997-04-29|Development Center For Biotechnology|Process for preparing 2-cyano-3,5-dimethyl-4-methoxypyridine|

---

US6599927B2|1996-10-11|2003-07-29|Astrazeneca Ab|Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome|

---

TW385306B|1996-11-14|2000-03-21|Takeda Chemical Industries Ltd|Method for producing crystals of benzimidazole derivatives|

---

SE510666C2|1996-12-20|1999-06-14|Astra Ab|New Crystal Modifications|

---

US6437139B1|1997-05-06|2002-08-20|Pdi-Research Laboratories, Inc.|Synthesis of pharmaceutically useful pyridine derivatives|

---

CA2204580A1|1997-05-06|1998-11-06|Michel Zoghbi|Synthesis of pharmaceutically useful pyridine derivatives|

---

KR100463031B1|1997-05-26|2005-04-06|동아제약주식회사|New preparation method of 5-methoxy-2- [3,5-dimethyl-4-methoxypyridylmethyl) sulfinyl] -1H-benzimidazole|

---

SE9702000D0|1997-05-28|1997-05-28|Astra Ab|New pharmaceutical formulation|

---

SE510650C2|1997-05-30|1999-06-14|Astra Ab|New association|

---

US6747155B2|1997-05-30|2004-06-08|Astrazeneca Ab|Process|

---

WO1998054172A1|1997-05-30|1998-12-03|Dr. Reddy's Research Foundation|Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them|

---

SE510643C2|1997-06-27|1999-06-14|Astra Ab|Thermodynamically stable omeprazole sodium form B|

---

CA2295817C|1997-07-11|2008-02-12|Eisai Co., Ltd.|Method for producing pyridine compound|

---

SI9700186B|1997-07-14|2006-10-31|Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D.|Novel pharmaceutical preparation with controlled release of active healing substances|

---

SI1003554T1|1997-07-25|2005-04-30|Altana Pharma Ag|Proton pump inhibitor in therapeutic combination with antibacterial substances|

---

US6296876B1|1997-10-06|2001-10-02|Isa Odidi|Pharmaceutical formulations for acid labile substances|

---

US7230014B1|1997-10-14|2007-06-12|Eisai Co., Ltd.|Pharmaceutical formulation comprising glycine as a stabilizer|

---

SE9704183D0|1997-11-14|1997-11-14|Astra Ab|New process|

---

US6096340A|1997-11-14|2000-08-01|Andrx Pharmaceuticals, Inc.|Omeprazole formulation|

---

SI1037634T1|1997-12-08|2006-02-28|Altana Pharma Ag|Oral administration form comprising a proton pump inhibitor |

---

DE19754324A1|1997-12-08|1999-06-10|Byk Gulden Lomberg Chem Fab|Easily prepared oral dosage forms for acid-labile drugs, especially proton pump inhibitors|

---

SE9704870D0|1997-12-22|1997-12-22|Astra Ab|New pharmaceutical formulation I|

---

SE9704869D0|1997-12-22|1997-12-22|Astra Ab|New pharmaceutical formulaton II|

---

US6159968A|1998-01-15|2000-12-12|University Of Cincinnati|Activation of chloride channels for correction of defective chloride transport|

---

US6197962B1|1998-01-26|2001-03-06|Kuraray Co., Ltd.|Method for producing 2-sulfonylpyridine derivatives and method for producing 2-{[methyl]thio}-1H-benzimidazole derivatives|

---

US6350876B2|1998-01-26|2002-02-26|Kuraray Co., Ltd.|4-chloro-3,5-dimethyl-2-sulfonyl pyridines|

---

IT1299198B1|1998-03-05|2000-02-29|Nicox Sa|NITRATED SALTS OF ANTI-ULCER DRUGS|

---

ES2559766T3|1998-05-18|2016-02-15|Takeda Pharmaceutical Company Limited|Disintegrable tablets in the mouth|

---

US6303787B1|1998-05-27|2001-10-16|Natco Pharma Limited|Intermediates and an improved process for the preparation of Omeprazole employing the said intermediates|

---

ZA9810765B|1998-05-28|1999-08-06|Ranbaxy Lab Ltd|Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.|

---

WO2000000474A1|1998-06-26|2000-01-06|Russinsky Limited|Pyridine building blocks as intermediates in the synthesis of pharmaceutically active compounds|

---

SI20019A|1998-07-13|2000-02-29|LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d.|An improved process for synthesis of 5-methoxy-2-/methyl/ sulphynyl-1h-benzimidazol|

---

UA67788C2|1998-08-10|2004-07-15|Ріджентс Оф Зе Юніверсіті Оф Каліфорніа|Prodrugs of the proton pump inhibitorsand pharmaceutical composition based thereon|

---

US6093734A|1998-08-10|2000-07-25|Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin|Prodrugs of proton pump inhibitors|

---

US6166213A|1998-08-11|2000-12-26|Merck & Co., Inc.|Omeprazole process and compositions thereof|

---

US6191148B1|1998-08-11|2001-02-20|Merck & Co., Inc.|Omerazole process and compositions thereof|

---

DK1105105T3|1998-08-12|2006-07-17|Altana Pharma Ag|Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles|

---

DE19843413C1|1998-08-18|2000-03-30|Byk Gulden Lomberg Chem Fab|New salt form of pantoprazole|

---

US6733778B1|1999-08-27|2004-05-11|Andrx Pharmaceuticals, Inc.|Omeprazole formulation|

---

US6174548B1|1998-08-28|2001-01-16|Andrx Pharmaceuticals, Inc.|Omeprazole formulation|

---

SE9803772D0|1998-11-05|1998-11-05|Astra Ab|Pharmaceutical formulation|

---

AU1054899A|1998-11-06|2000-05-29|Dong-A Pharmaceutical Co., Ltd.|Method of preparing sulfide derivatives|

---

CN1347413A|1998-11-10|2002-05-01|阿斯特拉曾尼卡有限公司|Crystalline form of omeprazole|

---

IL142703A|1998-11-10|2006-04-10|Astrazeneca Ab|Crystalline form of omeprazole|

---

JP3926936B2|1998-11-16|2007-06-06|エーザイ・アール・アンド・ディー・マネジメント株式会社|Sulfoxide derivative / acetone complex and production method thereof|

---

SE9900274D0|1999-01-28|1999-01-28|Astra Ab|New compound|

---

US6852739B1|1999-02-26|2005-02-08|Nitromed Inc.|Methods using proton pump inhibitors and nitric oxide donors|

---

TWI243672B|1999-06-01|2005-11-21|Astrazeneca Ab|New use of compounds as antibacterial agents|

---

MXPA01012659A|1999-06-07|2003-09-04|Altana Pharma Ag|Novel preparation and administration form comprising an acid-labile active compound.|

---

IL130602D0|1999-06-22|2000-06-01|Dexcel Ltd|Stable benzimidazole formulation|

---

US6555139B2|1999-06-28|2003-04-29|Wockhardt Europe Limited|Preparation of micron-size pharmaceutical particles by microfluidization|

---

US6245913B1|1999-06-30|2001-06-12|Wockhardt Europe Limited|Synthetic procedure for 5-methoxy-2-[-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole|

---

CN1183127C|1999-08-26|2005-01-05|艾伊法马公司|Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same|

---

US6262085B1|1999-08-26|2001-07-17|Robert R. Whittle|Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same|

---

US6312723B1|1999-08-26|2001-11-06|Robert R. Whittle|Pharmaceutical unit dosage form|

---

CA2382838A1|1999-08-26|2001-03-01|Frederick D. Sancilio|Ft-raman spectroscopic measurement of omeprazole isomer ratio in a composition|

---

EP1595879A3|1999-08-26|2010-01-27|aaiPharma Inc.|Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same|

---

US6312712B1|1999-08-26|2001-11-06|Robert R. Whittle|Method of improving bioavailability|

---

US6780880B1|1999-08-26|2004-08-24|Robert R. Whittle|FT-Raman spectroscopic measurement|

---

US6326384B1|1999-08-26|2001-12-04|Robert R. Whittle|Dry blend pharmaceutical unit dosage form|

---

US6369087B1|1999-08-26|2002-04-09|Robert R. Whittle|Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same|

---

US6262086B1|1999-08-26|2001-07-17|Robert R. Whittle|Pharmaceutical unit dosage form|

---

US6316020B1|1999-08-26|2001-11-13|Robert R. Whittle|Pharmaceutical formulations|

---

US6268385B1|1999-08-26|2001-07-31|Robert R. Whittle|Dry blend pharmaceutical formulations|

---

US6228400B1|1999-09-28|2001-05-08|Carlsbad Technology, Inc.|Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same|

---

SE9903831D0|1999-10-22|1999-10-22|Astra Ab|Formulation of substituted benzimidazoles|

---

DE19951960C2|1999-10-28|2002-06-27|Gruenenthal Gmbh|Process for the preparation of benzimidazole derivatives suitable as ulcer therapeutics|

---

CA2290893C|1999-11-16|2007-05-01|Bernard Charles Sherman|Magnesium omeprazole|

---

DE19959419A1|1999-12-09|2001-06-21|Ratiopharm Gmbh|Stable pharmaceutical preparations comprising a benzimidazole and process for their preparation|

---

EP1248790A1|1999-12-17|2002-10-16|Ariad Pharmaceuticals, Inc.|Proton pump inhibitors|

---

US6787342B2|2000-02-16|2004-09-07|Merial Limited|Paste formulations|

---

SE0000774D0|2000-03-08|2000-03-08|Astrazeneca Ab|New formulation|

---

SE0000773D0|2000-03-08|2000-03-08|Astrazeneca Ab|New formulation|

---

US6306435B1|2000-06-26|2001-10-23|Yung Shin Pharmaceutical Industrial Co. Ltd.|Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same|

---

SE0002476D0|2000-06-30|2000-06-30|Astrazeneca Ab|New compounds|

---

US6544556B1|2000-09-11|2003-04-08|Andrx Corporation|Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor|

---

US20020064555A1|2000-09-29|2002-05-30|Dan Cullen|Proton pump inhibitor formulation|

---

WO2002045686A2|2000-12-07|2002-06-13|Altana Pharma Ag|Pharmaceutical paste comprising an acid-labile active ingredient|

---

PT1341528E|2000-12-07|2012-03-20|Nycomed Gmbh|Rapidly disintegrating tablet comprising an acid-labile active ingredient|

---

ES2403238T3|2000-12-07|2013-05-16|Takeda Gmbh|Pharmaceutical preparation in the form of a suspension comprising an active ingredient labile in acidic medium|

---

YU61103A|2001-02-02|2006-05-25|Teva Pharmaceutical Industries Ltd.|Processes for the production of substituted 2- sulfinyl-1h-benzimidazoles|

---

US6645946B1|2001-03-27|2003-11-11|Pro-Pharmaceuticals, Inc.|Delivery of a therapeutic agent in a formulation for reduced toxicity|

---

SE0101379D0|2001-04-18|2001-04-18|Diabact Ab|Composition that inhibits gastric acid secretion|

---

SI20875A|2001-04-25|2002-10-31|LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d.|Crystal form of omeprazole|

---

US8206741B2|2001-06-01|2012-06-26|Pozen Inc.|Pharmaceutical compositions for the coordinated delivery of NSAIDs|

---

JP4756823B2|2001-06-01|2011-08-24|ポーゼンインコーポレイテッド|Pharmaceutical composition for coordinated delivery of NSAIDs|

---

DE10140492A1|2001-08-17|2003-08-14|Gruenenthal Gmbh|Hydrates of optionally substituted 2-methylthio-1H-benzimidazoles and process for their preparation|

---

SE0102993D0|2001-09-07|2001-09-07|Astrazeneca Ab|New self emulsifying drug delivery system|

---

AU2002332178B2|2001-09-18|2005-12-08|Zeria Pharmaceutical Co., Ltd.|Benzimidazole derivatives|

---

US8101209B2|2001-10-09|2012-01-24|Flamel Technologies|Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles|

---

DK1459737T3|2001-10-17|2013-01-02|Takeda Pharmaceutical|Granules containing acid unstable chemical in large quantity|

---

US7855082B1|2001-10-31|2010-12-21|Astrazeneca Ab|Raman spectroscopic method for determining the ratio of 5-methoxy and 6-methoxy isomers of omeprazole|

---

CA2472103A1|2002-01-25|2003-08-07|Santarus, Inc.|Transmucosal delivery of proton pump inhibitors|

---

ES2286408T3|2002-03-05|2007-12-01|Astrazeneca Ab|SALES OF ALQUILAMONIO DE OMEPRAZOL E ESOMEPRAZOL.|

---

IL164221D0|2002-04-09|2005-12-18|Flamel Tech Sa|Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim|

---

DE60325709D1|2002-04-09|2009-02-26|Flamel Tech Sa|ORAL AQUEOUS SUSPENSION CONTAINING MICRO CAPSULES FOR THE CONTROLLED RELEASE OF ACTIVE SUBSTANCES|

---

US20030228363A1|2002-06-07|2003-12-11|Patel Mahendra R.|Stabilized pharmaceutical compositons containing benzimidazole compounds|

---

US20040034078A1|2002-06-14|2004-02-19|Agouron Pharmaceuticals, Inc.|Benzimidazole inhibitors of poly polymerase|

---

AT323695T|2002-07-19|2006-05-15|Winston Pharmaceuticals Llc|BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS FOR PROTONAL PUMP INHIBITORS|

---

TW200410955A|2002-07-29|2004-07-01|Altana Pharma Ag|Novel salt of -PANTOPRAZOLE|

---

CA2493618A1|2002-08-01|2004-02-12|Nitromed, Inc.|Nitrosated proton pump inhibitors, compositions and methods of use|

---

SE0203065D0|2002-10-16|2002-10-16|Diabact Ab|Gastric acid secretion inhibiting composition|

---

MY148805A|2002-10-16|2013-05-31|Takeda Pharmaceutical|Controlled release preparation|

---

EP1552833B1|2002-10-16|2016-12-28|Takeda Pharmaceutical Company Limited|Process for producing an amorphous optically active isomer of lansoprazole|

---

SE0203092D0|2002-10-18|2002-10-18|Astrazeneca Ab|Method for the synthesis of a benzimidazole compound|

---

FR2845915B1|2002-10-21|2006-06-23|Negma Gild|USE OF TENATOPRAZOLE FOR THE TREATMENT OF GASTRO-OESOPHAGEAL REFLUX|

---

EP1556043A1|2002-10-22|2005-07-27|Ranbaxy Laboratories, Ltd.|Amorphous form of esomeprazole salts|

---

DE10254167A1|2002-11-20|2004-06-09|Icon Genetics Ag|Process for the control of cellular processes in plants|

---

AR042278A1|2002-12-06|2005-06-15|Altana Pharma Ag|A PROCEDURE FOR THE PREPARATION OF- PANTOPRAZOL|

---

PL375818A1|2002-12-06|2005-12-12|Altana Pharma Ag|Process for preparing optically pure active compounds|

---

FR2848555B1|2002-12-16|2006-07-28|Negma Gild|ENANTIOMEROF TENATOPRAZOLE AND ITS THERAPEUTIC APPLICATION|

---

AU2003303240A1|2002-12-19|2004-07-14|Eva Pharmaceutical Industries Ltd.|Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates|

---

US20040166162A1|2003-01-24|2004-08-26|Robert Niecestro|Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid|

---

JP2006518751A|2003-02-20|2006-08-17|サンタラスインコーポレイティッド|Novel formulation for rapid and sustained suppression of gastric acid, omeprazole antacid complex-immediate release|

---

US20040185119A1|2003-02-26|2004-09-23|Theuer Richard C.|Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency|

---

ES2245277T1|2003-03-12|2006-01-01|Teva Pharmaceutical Industries Limited|SOLIDOS CRYSTALS AND AMORPHES OF PANTOPRAZOL AND PROCEDURES FOR THEIR PREPARATION.|

---

JP4355703B2|2003-03-13|2009-11-04|エーザイ・アール・アンド・ディー・マネジメント株式会社|Preventive or therapeutic agent for bruxism|

---

US20040185092A1|2003-03-18|2004-09-23|Yih Ming Hsiao|Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use|

---

WO2004087702A2|2003-03-28|2004-10-14|Sidem Pharma|Method for the enantioselective preparation of sulphoxide derivatives|

---

FR2852956B1|2003-03-28|2006-08-04|Negma Gild|PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF SULFOXIDE DERIVATIVES|

---

CL2004000983A1|2003-05-08|2005-03-04|Altana Pharma Ag|ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF A TABLET THAT INCLUDES DIHYDRATED MAGNETIC PANTOPRAZOL, WHERE THE TABLET FORM IS COMPOSED BY A NUCLEUS, A MIDDLE COAT AND AN OUTER LAYER; AND USE OF PHARMACEUTICAL COMPOSITION IN ULCERAS AND|

---

PE20050150A1|2003-05-08|2005-03-22|Altana Pharma Ag|A DOSAGE FORM CONTAINING-PANTOPRAZOLE AS AN ACTIVE INGREDIENT|

---

US7524837B2|2003-05-12|2009-04-28|Janssen Pharmaceutica N.V.|Benzotriazapinone salts and methods for using same|

---

EP1615913A2|2003-06-10|2006-01-18|Teva Pharmaceutical Industries Limited|Process for preparing 2-methyl sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole|

---

EP2112920B1|2003-06-26|2018-07-25|Intellipharmaceutics Corp.|Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient|

---

PL379542A1|2003-07-15|2006-10-02|Allergan, Inc.|Process for preparing isomerically pure prodrugs of proton pump inhibitors|

---

US20050037070A1|2003-07-18|2005-02-17|Santarus, Inc.|Pharmaceutical formulatins useful for inhibiting acid secretion and methods for making and using them|

---

CA2531566C|2003-07-18|2013-05-07|Santarus, Inc.|Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders|

---

US8993599B2|2003-07-18|2015-03-31|Santarus, Inc.|Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them|

---

AU2004268383A1|2003-09-03|2005-03-10|Agi Therapeutics Limited|Proton pump inhibitor formulations, and methods of preparing and using such formulations|

---

SE0302382D0|2003-09-04|2003-09-04|Astrazeneca Ab|New salts II|

---

SE0302381D0|2003-09-04|2003-09-04|Astrazeneca Ab|New salts I|

---

US8541026B2|2004-09-24|2013-09-24|Abbvie Inc.|Sustained release formulations of opioid and nonopioid analgesics|

---

TWI372066B|2003-10-01|2012-09-11|Wyeth Corp|Pantoprazole multiparticulate formulations|

---

US20060241037A1|2003-10-03|2006-10-26|Allergan Inc.|Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs|

---

US20050075371A1|2003-10-03|2005-04-07|Allergan, Inc.|Methods and compositions for the oral administration of prodrugs of proton pump inhibitors|

---

US20070202119A1|2003-10-24|2007-08-30|Ashdown Martin L|Method Of Therapy|

---

US20070292498A1|2003-11-05|2007-12-20|Warren Hall|Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers|

---

EP1716136A1|2004-02-11|2006-11-02|Ulkar Kimya Sanayii Ve Ticaret A.S.|Pyridine benzimidazole sulfoxides of high purity|

---

JP2007523163A|2004-02-18|2007-08-16|アラーガン、インコーポレイテッド|Methods and compositions for the administration of prodrugs of proton pump inhibitors|

---

AU2005216863A1|2004-02-18|2005-09-09|Allergan, Inc.|Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors|

---

SE0400410D0|2004-02-20|2004-02-20|Astrazeneca Ab|New compounds|

---

US20080287502A1|2004-03-30|2008-11-20|Dermatrends, Inc.|Transdermal Administration of Proton Pump Inhibitors|

---

PT1740571E|2004-04-28|2009-09-02|Hetero Drugs Ltd|A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers|

---

US8906940B2|2004-05-25|2014-12-09|Santarus, Inc.|Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them|

---

US8815916B2|2004-05-25|2014-08-26|Santarus, Inc.|Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them|

---

AT456566T|2004-05-28|2010-02-15|Hetero Drugs Ltd|NEW STEREOSELECTIVE SYNTHESIS OF BENZIMIDAZOLSULFOXIDEN|

---

US20050267157A1|2004-05-28|2005-12-01|David White|Magnesium-S-omeprazole|

---

CA2568652A1|2004-06-02|2005-12-15|Altana Pharma Ag|Process for the preparation of pyridin-2-ylmethylsulphinyl-1h-benzimidazol compounds|

---

US8394409B2|2004-07-01|2013-03-12|Intellipharmaceutics Corp.|Controlled extended drug release technology|

---

US20060024362A1|2004-07-29|2006-02-02|Pawan Seth|Composition comprising a benzimidazole and process for its manufacture|

---

US10624858B2|2004-08-23|2020-04-21|Intellipharmaceutics Corp|Controlled release composition using transition coating, and method of preparing same|

---

CA2579665C|2004-09-13|2014-03-18|Takeda Pharmaceutical Company Limited|Method and apparatus for producing oxidized compound|

---

WO2006053383A1|2004-11-22|2006-05-26|Anadis Ltd|Bioactive compositions|

---

CN101111233A|2004-12-23|2008-01-23|兰贝克赛实验室有限公司|Stable oral benzimidazole compositions and process of preparation thereof|

---

EP1845982A2|2005-02-02|2007-10-24|Ranbaxy Laboratories Limited|Stable oral benzimidazole compositions prepared by non-aqueous layering process|

---

WO2006090845A1|2005-02-25|2006-08-31|Takeda Pharmaceutical Company Limited|Method for producing granules|

---

US7981908B2|2005-05-11|2011-07-19|Vecta, Ltd.|Compositions and methods for inhibiting gastric acid secretion|

---

US7803817B2|2005-05-11|2010-09-28|Vecta, Ltd.|Composition and methods for inhibiting gastric acid secretion|

---

EP1891043A1|2005-06-15|2008-02-27|Hetero Drugs Limited|Amorphous esomeprazole hydrate|

---

CA2613875C|2005-07-04|2018-09-25|Ramu Krishnan|Improved drug or pharmaceutical compounds and a preparation thereof|

---

EP1904064A4|2005-07-07|2009-12-02|Reddys Lab Ltd Dr|Omeprazole form b|

---

TWI394750B|2005-07-26|2013-05-01|Takeda Gmbh|Isotopically substituted proton pump inhibitors|

---

US7601737B2|2005-07-26|2009-10-13|Nycomed Gmbh|Isotopically substituted proton pump inhibitors|

---

JP5289951B2|2005-07-26|2013-09-11|タケダゲゼルシャフトミットベシュレンクテルハフツング|Isotopically substituted pantoprazole|

---

CA2624179A1|2005-10-06|2007-04-12|Auspex Pharmaceuticals, Inc.|Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties|

---

US7576219B2|2005-10-26|2009-08-18|Hanmi Pharm. Co., Ltd|Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same|

---

WO2007067128A1|2005-12-05|2007-06-14|Astrazeneca Ab|New process for the preparation of esomeprazole non-salt form|

---

EP1801110A1|2005-12-22|2007-06-27|KRKA, tovarna zdravil, d.d., Novo mesto|Esomeprazole arginine salt|

---

US10064828B1|2005-12-23|2018-09-04|Intellipharmaceutics Corp.|Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems|

---

US8486450B2|2005-12-28|2013-07-16|Takeda Pharmaceutical Company Limited|Method of producing solid preparation disintegrating in the oral cavity|

---

AT428707T|2005-12-28|2009-05-15|Union Quimico Farma|PROCESS FOR PREPARING THE-ENANTIOMER OF OMEPRAZOLE|

---

EP2007360B1|2006-04-03|2014-11-26|Isa Odidi|Controlled release delivery device comprising an organosol coat|

---

US10960077B2|2006-05-12|2021-03-30|Intellipharmaceutics Corp.|Abuse and alcohol resistant drug composition|

---

US7786309B2|2006-06-09|2010-08-31|Apotex Pharmachem Inc.|Process for the preparation of esomeprazole and salts thereof|

---

US7863330B2|2006-06-14|2011-01-04|Rottapharm S.P.A.|Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders|

---

KR101489370B1|2006-07-25|2015-02-03|벡타 리미티드|Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with ppi|

---

WO2008036201A1|2006-09-19|2008-03-27|Alevium Pharmaceuticals, Inc.|Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety|

---

CA2665226C|2006-10-05|2014-05-13|Santarus, Inc.|Novel formulations of proton pump inhibitors and methods of using these formulations|

---

AU2007317561A1|2006-10-27|2008-05-15|The Curators Of The University Of Missouri|Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same|

---

ZA200904573B|2006-12-22|2010-09-29|Ironwood Pharmaceuticals Inc|Compositions comprising bile acid sequestrants for treating esophageal disorders|

---

EP1947099A1|2007-01-18|2008-07-23|LEK Pharmaceuticals D.D.|Process for solvent removal from omeprazole salts|

---

EP2114919A2|2007-01-31|2009-11-11|Krka Tovarna Zdravil, D.D., Novo Mesto|Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic seperation|

---

US20080194307A1|2007-02-13|2008-08-14|Jeff Sanger|Sports-based game of chance|

---

KR101522219B1|2007-02-21|2015-05-21|시플라 리미티드|Process for the preparation of esomeprazole magnesium dihydrate|

---

KR20090121388A|2007-03-15|2009-11-25|썬 파마 어드밴스트 리서치 컴패니 리미티드|Novel prodrugs|

---

US8492551B2|2007-06-07|2013-07-23|Aurobindo Pharma. Ltd.|Process for preparing an optically active proton pump inhibitor|

---

WO2009010937A1|2007-07-17|2009-01-22|Ranbaxy Laboratories Limited|Process for the preparation op pantoprazole sodium and pantoprazole sodium sesquihydrate|

---

WO2009066317A2|2007-08-20|2009-05-28|Macleods Pharmaceuticals Limited|Process for the preparation of pantoprazole sodium|

---

US20090092658A1|2007-10-05|2009-04-09|Santarus, Inc.|Novel formulations of proton pump inhibitors and methods of using these formulations|

---

US8106210B2|2007-10-08|2012-01-31|Hetero Drugs Limited|Polymorphs of esomeprazole salts|

---

CN101450939B|2007-12-05|2013-06-19|沈阳药科大学|Novel benzimidazoles compounds|

---

EP2252274A4|2008-02-20|2011-05-11|Univ Missouri|Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same|

---

US8911787B2|2008-02-26|2014-12-16|Ranbaxy Laboratories Limited|Stable oral benzimidazole compositions and process of preparation thereof|

---

EP2285351A2|2008-04-15|2011-02-23|Schering Corporation|Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas|

---

EP2278957A2|2008-04-15|2011-02-02|Schering Corporation|Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas|

---

KR101044880B1|2008-06-12|2011-06-28|일양약품주식회사|Process for Preparing Intermediate Compound for Synthesizing an Antiulcerant|

---

EP2147918A1|2008-07-21|2010-01-27|LEK Pharmaceuticals D.D.|Process for the preparation of S-omeprazole magnesium in a stable form|

---

CH699302B1|2008-08-11|2012-03-15|Mepha Gmbh|An oral pharmaceutical formulation for omeprazole containing a specific release layer.|

---

CN102209529A|2008-09-09|2011-10-05|阿斯利康有限公司|Method for delivering a pharmaceutical composition to patient in need thereof|

---

US20100093747A1|2008-10-10|2010-04-15|Erica Brook Goodhew|Method of inducing negative chemotaxis|

---

EP2264024A1|2008-10-14|2010-12-22|LEK Pharmaceuticals d.d.|Process for the preparation of enantiomerically enriched proton pump inhibitors|

---

WO2010134099A1|2009-05-21|2010-11-25|Cadila Healthcare Limited|One pot process for preparing omeprazole and related compounds|

---

US9122778B2|2009-05-27|2015-09-01|Biotempus Limited|Methods of treating diseases|

---

KR20120093140A|2009-06-25|2012-08-22|포젠 인크.|Method for treating a patient in need of aspirin therapy|

---

AU2010263304A1|2009-06-25|2012-02-02|Astrazeneca Ab|Method for treating a patient at risk for developing an NSAID-associated ulcer|

---

WO2011058569A1|2009-11-12|2011-05-19|Hetero Research Foundation|Process for the resolution of omeprazole|

---

WO2011080501A2|2009-12-29|2011-07-07|Orexo Ab|New pharmaceutical dosage form for the treatment of gastric acid-related disorders|

---

WO2011080500A2|2009-12-29|2011-07-07|Orexo Ab|New pharmaceutical dosage form for the treatment of gastric acid-related disorders|

---

WO2011080502A2|2009-12-29|2011-07-07|Orexo Ab|New pharmaceutical dosage form for the treatment of gastric acid-related disorders|

---

EP2345408A3|2010-01-08|2012-02-29|Dr. Reddy's Laboratories Ltd.|Acid labile drug formulations|

---

CN102140099A|2010-02-02|2011-08-03|山东轩竹医药科技有限公司|Novel pyridine derivative|

---

US9623622B2|2010-02-24|2017-04-18|Michael Baines|Packaging materials and methods|

---

WO2012027331A1|2010-08-27|2012-03-01|Ironwood Pharmaceuticals, Inc.|Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders|

---

US9233103B2|2011-03-25|2016-01-12|Takeda Pharmaceuticals U.S.A., Inc.|Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy|

---

CN103826632B|2011-08-26|2017-04-12|国立大学法人名古屋大学|Osteogenesis promoter and use thereof|

---

EA028342B1|2011-09-09|2017-11-30|Мерк Шарп И Доум Корп.|Methods for treating pneumonia|

---

WO2013081566A1|2011-11-25|2013-06-06|Mahmut Bilgic|A formulation comprising benzimidazole|

---

EP2601947A1|2011-12-05|2013-06-12|Abo Bakr Mohammed Ali Al-Mehdar|Fixed-dose combination for treatment of helicobacter pylori associated diseases|

---

EP2797600A4|2011-12-28|2015-09-16|Pozen Inc|Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid|

---

CN102584792B|2012-01-06|2014-06-11|南京优科生物医药研究有限公司|Method for preparing high-purity esomeprazole|

---

CN104203938A|2012-01-21|2014-12-10|朱比兰特生命科学有限公司|Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers|

---

US8809314B1|2012-09-07|2014-08-19|Cubist Pharmacueticals, Inc.|Cephalosporin compound|

---

US8476425B1|2012-09-27|2013-07-02|Cubist Pharmaceuticals, Inc.|Tazobactam arginine compositions|

---

EA201591338A1|2013-01-15|2016-01-29|Айронвуд Фармасьютикалз, Инк.|GASTRORETENTIVE MEDICAL FORM OF SECRESTRANATE OF BILIC ACIDS, SLOWLY RELEASED FOR ORAL APPLICATION|

---

US20140275000A1|2013-03-15|2014-09-18|Cubist Pharmaceuticals, Inc.|Ceftolozane pharmaceutical compositions|

---

US9872906B2|2013-03-15|2018-01-23|Merck Sharp & Dohme Corp.|Ceftolozane antibiotic compositions|

---

KR102226197B1|2013-03-15|2021-03-11|머크 샤프 앤드 돔 코포레이션|Ceftolozane antibiotic compositions|

---

GB201306720D0|2013-04-12|2013-05-29|Special Products Ltd|Formulation|

---

ES2800603T3|2013-09-09|2021-01-04|Merck Sharp & Dohme|Treatment of infections with ceftolozane / tazobactam in patients with renal impairment|

---

US8906898B1|2013-09-27|2014-12-09|Calixa Therapeutics, Inc.|Solid forms of ceftolozane|

---

US9457011B2|2014-02-25|2016-10-04|Muslim D. Shahid|Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor|

---

FR3018812A1|2014-03-21|2015-09-25|Minakem|NOVEL INTERMEDIATE PHASE OF FORM A OF MAGNESIUM SALT DIHYDRATE OF AN OMEPRAZOLE ENANTIOMER|

---

WO2015155281A1|2014-04-11|2015-10-15|Sanovel Ilac Sanayi Ve Ticaret A.S.|Pharmaceutical combinations of dabigatran and proton pump inhibitors|

---

WO2015155307A1|2014-04-11|2015-10-15|Sanovel Ilac Sanayi Ve Ticaret A.S.|Pharmaceutical combinations of rivaroxaban and proton pump inhibitors|

---

CN104045627A|2014-05-21|2014-09-17|丽珠医药集团股份有限公司|Purification method of omeprazole|

---

CA2952069A1|2014-06-16|2015-12-23|University Of Rochester|Small molecule anti-scarring agents|

---

US20180015118A1|2015-02-03|2018-01-18|Ironwood Pharmaceuticals, Inc.|Methods of treating upper gastrointestinal disorders in ppi refractory gerd|

---

WO2016174664A1|2015-04-29|2016-11-03|Dexcel Pharma Technologies Ltd.|Orally disintegrating compositions|

---

US10736855B2|2016-02-25|2020-08-11|Dexcel Pharma Technologies Ltd.|Compositions comprising proton pump inhibitors|

---

US10076494B2|2016-06-16|2018-09-18|Dexcel Pharma Technologies Ltd.|Stable orally disintegrating pharmaceutical compositions|

---

EP3496714A4|2016-08-11|2020-04-22|Adamis Pharmaceuticals Corporation|Drug compositions|

---

EP3292862A1|2016-09-07|2018-03-14|Sandoz Ag|Omeprazole formulations|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

SE7804231A|SE7804231L|1978-04-14|1978-04-14|Gastric acid secretion|

---